TIDMHZD
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) Millennium International Management LP
Company dealt in Horizon Therapeutics plc
Class of relevant security to which IE00BQPVQZ61
the dealings being disclosed relate
(Note 2)
Date of dealing 12(th) December 2022
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 1,551,488 17,809
(0.684%) (0.008%)
(2) Derivatives (other than options) 0 621
(0.000%) (0.000%)
(3) Options and agreements to purchase/sell 1,120,400 337,800
(0.494%) (0.149%)
Total 2,671,888 356,230
(1.179%) (0.157%)
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
Purchase 5,671 111.89
Sale 200 111.89
Purchase 100 111.90
Purchase 5,078 111.80
Purchase 12,731 111.50
Purchase 49,825 111.72
Purchase 1,195 111.33
Purchase 22 111.79
Purchase 1,962 111.52
Purchase 5,555 111.98
Purchase 412 111.35
Sale 60 111.88
Sale 85 112.19
Purchase 700 111.93
Purchase 100 111.91
Purchase 2,099 111.95
Purchase 12,955 111.94
Purchase 7,433 111.99
Purchase 54 112.29
Purchase 169 112.31
Purchase 2,100 112.00
Purchase 1,557 111.96
Sale 45 111.96
Purchase 2,871 112.36
Purchase 175 112.20
Purchase 11,300 111.97
Purchase 1,609 111.37
Purchase 4,860 111.36
Sale 417 112.23
Sale 300 112.18
Sale 68 112.26
Purchase 4,655 111.40
Purchase 5,474 111.48
Sale 100 111.42
Purchase 1,258 112.22
Purchase 80,046 111.00
Purchase 4,990 111.25
Purchase 13 111.62
Purchase 300 111.28
Purchase 8,610 111.49
Sale 144 111.27
Purchase 254 111.32
Purchase 110 111.23
Purchase 548 111.41
Purchase 1,088 111.29
Purchase 118 111.26
Purchase 144 111.43
Sale 208 112.15
Purchase 100 111.51
Purchase 9,452 111.45
Purchase 888 111.46
Purchase 13,677 111.47
Purchase 1,580 111.39
Purchase 7,944 111.38
Purchase 65,923 111.24
Purchase 1,296 111.73
Purchase 915 110.96
Purchase 96,003 111.08
Purchase 300 111.53
Purchase 430 111.78
Sale 100 112.17
Sale 55 112.21
Sale 357 111.89
Sale 1,581 111.90
Sale 117 111.50
Sale 49 111.72
Sale 100 111.52
Sale 1,366 111.85
Sale 554 111.98
Sale 246 111.88
Sale 2,748 111.71
Sale 261 112.19
Sale 240 111.93
Sale 1,290 111.91
Sale 2,308 111.92
Sale 645 111.94
Sale 343 111.99
Sale 118 112.29
Sale 245 111.96
Sale 1,200 111.77
Sale 394 112.24
Purchase 199 112.36
Sale 146 112.28
Sale 1 112.39
Sale 118 112.27
Sale 325 112.30
Sale 252 112.20
Sale 100 112.40
Sale 50 112.38
Sale 132 112.33
Sale 381 111.75
Sale 7,128 111.76
Sale 38 112.32
Sale 132 112.12
Sale 8,250 112.23
Sale 328 112.25
Sale 2,216 112.18
Sale 2,060 112.26
Sale 251 111.70
Sale 48 111.49
Sale 286 112.11
Sale 1 111.27
Sale 491 112.10
Sale 219 111.60
Sale 2,194 111.41
Sale 953 111.43
Sale 1 112.15
Sale 276 112.16
Sale 146 112.01
Sale 143 111.73
Sale 116 111.61
Sale 396 112.17
Sale 497 112.21
Sale 31 112.08
Sale 1 112.47
Sale 9,114 111.50
Purchase 3,236 111.88
Sale 80 111.89
Sale 140 111.82
Sale 90 111.98
Sale 480 111.94
Sale 100 111.96
Sale 2,975 112.36
Purchase 33 112.25
Purchase 100 112.26
Sale 74 111.62
Sale 1,000 111.63
Purchase 44 111.43
Purchase 134 111.44
Sale 26 111.54
Sale 200 111.46
Purchase 21,558 111.89
Sale 1,079 111.89
Purchase 14,574 111.90
Sale 100 111.90
Purchase 7 111.80
Sale 719 111.80
Purchase 129,808 111.50
Sale 25,864 111.50
Purchase 3 111.72
Sale 2,979 111.72
Purchase 100 111.82
Sale 200 111.82
Purchase 3,070 111.33
Purchase 10,111 111.79
Sale 1,100 111.79
Sale 1,293 111.52
Purchase 94 111.85
Sale 10,075 111.85
Purchase 9,580 111.98
Sale 200 111.98
Sale 89 111.35
Sale 200 111.64
Purchase 1,054 111.74
Sale 744 111.74
Purchase 1,934 111.88
Sale 406 111.88
Sale 9,170 111.71
Purchase 395 112.04
Sale 3,333 112.04
Purchase 203 112.05
Sale 3,640 112.05
Sale 2,296 112.19
Purchase 1,952 111.93
Sale 236 111.93
Purchase 5,105 111.83
Sale 403 111.83
Purchase 3 111.81
Sale 335 111.81
Purchase 11,997 111.91
Sale 630 111.91
Purchase 3,945 111.92
Sale 577 111.92
Purchase 3,869 111.95
Sale 24 111.95
Purchase 16,065 111.94
Sale 1,881 111.94
Purchase 18,357 111.99
Sale 3,044 111.99
Purchase 100 112.03
Sale 7,900 112.03
Purchase 100 112.29
Sale 9,474 112.29
Purchase 1,102 112.31
Sale 20,972 112.31
Sale 1,672 111.84
Purchase 8,257 111.87
Sale 32 111.87
Purchase 8,846 112.06
Purchase 9,608 112.00
Sale 12,799 112.00
Purchase 600 111.96
Purchase 4,023 111.77
Sale 4,941 111.77
Purchase 14,695 112.24
Sale 11,668 112.24
Purchase 21 112.36
Sale 31,284 112.36
Purchase 300 112.09
Sale 1,600 112.09
Purchase 64 112.28
Sale 22,154 112.28
Sale 14,297 112.37
Purchase 40 112.39
Sale 7,297 112.39
Sale 5,992 112.27
Purchase 153 112.30
Sale 16,324 112.30
Purchase 300 112.20
Sale 55,072 112.20
Purchase 2,912 111.97
Sale 1,389 111.97
Sale 3,500 112.46
Purchase 313 112.35
Sale 12,705 112.35
Sale 3,005 112.48
Sale 1,679 112.45
Sale 7,826 112.40
Purchase 40 112.38
Sale 22,748 112.38
Purchase 988 112.33
Sale 2,024 112.33
Purchase 10,134 111.75
Sale 334 111.75
Purchase 4,938 111.76
Sale 691 111.76
Purchase 1,172 112.32
Sale 20,817 112.32
Purchase 333 112.34
Sale 5,809 112.34
Purchase 1,836 111.37
Sale 200 111.37
Purchase 2,767 111.34
Purchase 1,366 111.36
Sale 3,268 111.36
Sale 1,152 112.12
Sale 2,161 112.23
Sale 87,160 112.25
Sale 188 112.18
Sale 10,855 112.26
Purchase 100 111.31
Sale 318 111.31
Purchase 2,166 111.40
Sale 2,568 111.40
Purchase 10,221 111.48
Sale 9,435 111.48
Purchase 22,137 111.42
Purchase 6,935 112.22
Sale 9,073 112.22
Sale 10,000 111.00
Purchase 16,300 111.25
Sale 2,689 111.25
Sale 2,471 111.70
Purchase 7,598 111.62
Sale 200 111.62
Purchase 500 111.59
Sale 316 111.59
Purchase 500 111.63
Sale 3,470 111.63
Sale 490 111.28
Purchase 8,449 111.49
Sale 1,846 111.49
Sale 11,076 112.11
Purchase 2,467 111.27
Sale 500 111.27
Purchase 1,326 111.32
Purchase 2,254 112.10
Sale 748 112.10
Purchase 3,541 111.60
Sale 5,634 111.60
Sale 523 111.23
Purchase 444 111.56
Purchase 1,617 111.41
Sale 516 111.29
Purchase 638 111.26
Sale 2,639 111.26
Purchase 3,568 111.43
Sale 282 111.43
Purchase 19,100 112.15
Sale 2,068 112.15
Sale 400 112.13
Sale 3,231 112.16
Purchase 766 112.01
Sale 8,356 112.01
Purchase 3,191 111.51
Sale 9,300 111.51
Sale 9,947 111.65
Purchase 8,000 111.30
Sale 2,607 111.30
Purchase 32,808 111.45
Sale 456 111.45
Purchase 3,402 111.44
Sale 3,237 111.44
Purchase 4,141 111.86
Sale 978 111.86
Purchase 3,835 111.54
Sale 6 111.54
Purchase 24,077 111.46
Sale 1,100 111.46
Purchase 17,091 111.47
Sale 690 111.47
Sale 374 111.39
Purchase 407 111.38
Sale 100 111.38
Sale 718 111.24
Sale 12,800 111.55
Sale 300 111.73
Sale 1,338 112.42
Purchase 1,500 112.02
Sale 422 112.02
Purchase 1,300 111.53
Sale 56 111.53
Purchase 602 111.61
Sale 3,668 111.61
Purchase 9,000 111.78
Sale 15 111.78
Sale 5,095 112.49
Purchase 1,030 112.17
Sale 2,843 112.17
Purchase 500 111.69
Sale 30 111.69
Sale 5,342 112.41
Purchase 56 110.30
Sale 1,083 112.44
Sale 739 112.43
Purchase 100 111.68
Sale 2,500 112.50
Purchase 646 111.57
Purchase 344 112.21
Sale 1,643 112.21
Purchase 100 112.07
Sale 43 112.07
Sale 272 112.08
Sale 197 112.47
Purchase 636 112.14
Sale 100 111.90
Sale 101 111.50
Sale 54 111.28
Sale 190 111.27
Sale 133 112.42
Sale 484 111.94
Purchase 643 112.00
Sale 42 111.96
Sale 55 112.25
(b) Derivatives transactions (other than options
transactions)
Product name, Nature of Number of relevant Price per unit (USD)
e.g. CFD transaction (Note securities (Note (Note 5)
6) 7)
(c) Options transactions in respect of existing relevant
securities
(i) Writing, selling, purchasing or varying
Number of
Product Writing, securities Type,
name, selling, to which e.g. Option money
e.g. purchasing, the option American, paid/received
call varying relates Exercise European Expiry per unit
option etc. (Note 7) price etc. date (Note 5)
Call
Option Purchasing 60,000 110.00 American 20/01/2023
Call
Option Purchasing 100,000 105.00 American 16/12/2022
Call
Option Selling 68,000 110.00 American 17/02/2023
Call
Option Purchasing 3,000 110.00 American 19/05/2023
Call
Option Selling 3,000 115.00 American 19/05/2023
Put
Option Purchasing 7,500 110.00 American 20/01/2023
Call
Option Selling 111,200 105.00 American 20/01/2023
Call
Option Purchasing 40,000 100.00 American 16/12/2022
Call
Option Selling 30,000 100.00 American 20/01/2023
(ii) Exercising
Product name, Number of securities Exercise price per unit (Note 5)
e.g. call option
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced. If none, this
should be stated.
None.
Is a Supplemental Form 8 attached? (Note 9) YES
Date of disclosure 13(th) December 2022
Contact name Roisin Nagle
Telephone number +44 203 192 8746
If a connected EFM, name of offeree/offeror with which
connected
If a connected EFM, state nature of connection (Note 10)
Ap32
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND
RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING
OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND
RIGHTS TO SUBSCRIBE FOR NEW SECURITIES
1. KEY INFORMATION
Full name of person making Millennium International Management LP
disclosure:
Name of offeror/offeree in relation Horizon Therapeutics plc
to whose relevant securities the
disclosure relates:
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Number of
securities
Product to which Type e.g.
Class of description option or Exercise American,
relevant e.g. call Written or derivative price European Expiry
security option purchased relates per unit etc. date
IE00BQPVQZ61 Call Option Written 20,000 110.00 American 20/01/2023
IE00BQPVQZ61 Call Option Purchased 808,500 125.00 American 20/01/2023
IE00BQPVQZ61 Call Option Purchased 44,600 110.00 American 20/01/2023
IE00BQPVQZ61 Call Option Written 7,500 110.00 American 20/01/2023
IE00BQPVQZ61 Call Option Written 100,000 105.00 American 16/12/2022
IE00BQPVQZ61 Call Option Purchased 8,600 90.00 American 20/01/2023
IE00BQPVQZ61 Call Option Written 1,200 125.00 American 20/01/2023
IE00BQPVQZ61 Call Option Purchased 29,100 100.00 American 17/02/2023
IE00BQPVQZ61 Call Option Written 29,100 110.00 American 17/02/2023
IE00BQPVQZ61 Put Option Written 1,500 90.00 American 19/05/2023
IE00BQPVQZ61 Call Option Written 26,400 120.00 American 20/01/2023
IE00BQPVQZ61 Put Option Purchased 11,400 95.00 American 16/12/2022
IE00BQPVQZ61 Put Option Written 10,000 95.00 American 16/12/2022
IE00BQPVQZ61 Put Option Purchased 15,000 100.00 American 16/12/2022
IE00BQPVQZ61 Call Option Purchased 100,000 90.00 American 16/12/2022
IE00BQPVQZ61 Put Option Written 93,400 85.00 American 16/12/2022
IE00BQPVQZ61 Put Option Written 40,500 90.00 American 16/12/2022
IE00BQPVQZ61 Call Option Purchased 40,000 130.00 American 20/01/2023
IE00BQPVQZ61 Call Option Purchased 50,000 120.00 American 16/12/2022
IE00BQPVQZ61 Put Option Written 7,500 85.00 American 20/01/2023
IE00BQPVQZ61 Call Option Purchased 200 65.00 American 20/01/2023
IE00BQPVQZ61 Put Option Written 200 65.00 American 20/01/2023
IE00BQPVQZ61 Call Option Purchased 3,000 110.00 American 19/05/2023
IE00BQPVQZ61 Call Option Written 3,000 115.00 American 19/05/2023
IE00BQPVQZ61 Put Option Written 7,500 110.00 American 20/01/2023
3. AGREEMENTS TO PURCHASE OR SELL
Full details should be given so that the nature of the interest or position
can be fully understood:
Ap33
4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS'
AND OTHER EMPLOYEE OPTIONS)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
It is not necessary to provide details on a Supplemental Form
with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be
stated.
For full details of disclosure requirements, see Rule 8 of the
Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish
Takeover Panel Act, 1997, Takeover Rules, 2022.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20221213005754/en/
CONTACT:
Millennium Partners, L.P.
SOURCE: Millennium Partners, L.P.
Copyright Business Wire 2022
(END) Dow Jones Newswires
December 13, 2022 10:25 ET (15:25 GMT)
Horizon Discovery (LSE:HZD)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Horizon Discovery (LSE:HZD)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
